Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Investigational drug GM604 has shown some intriguing results in a very small number of ALS patients
Posted on Thursday, January 22, 2015 - 10:13, By: Margaret Wahl
Biopharmaceutical company Genervon has announced what it considers encouraging results from a "compassionate use" trial of its experimental drug GM604 in a single patient with advanced amyotrophic lateral sclerosis (ALS).
In a phase 2 trial, the drug mexiletine was found to reduce the frequency of muscle cramps but not to affect motor or respiratory function
Posted on Tuesday, November 25, 2014 - 15:55, By: Margaret Wahl
Preliminary results of a trial of mexiletine in 60 people with amyotrophic lateral sclerosis (ALS) show the drug is reasonably safe and well tolerated and possibly effective for reducing the frequency and intensity of muscle cramps associated with this disorder. However, no benefits were seen in...
Israeli biotechnology company BrainStorm will test its adult stem cells, derived from bone marrow, in 48 ALS patients at three sites
Posted on Friday, June 13, 2014 - 10:06, By: Margaret Wahl
Israeli biotechnology company BrainStorm Cell Therapeutics has enrolled the first participant in a phase 2, U.S.-based trial of adult stem cell transplantation to treat amyotrophic lateral sclerosis (ALS).
This first of a series of three stories covering the 2014 MDA Clinical Conference discusses implications of new types of genetic testing
Posted on Monday, March 31, 2014 - 12:35, By: Margaret Wahl
“Knowing, if not all, is almost all,” said Matthew Harms, a neurologist and neurophysiologist from Washington University in St. Louis, in his presentation on genetic testing for neuromuscular disorders at the 2014 MDA Clinical Conference, held in Chicago March 16-19.
Findings show TDP43 protein transports RNA molecules in motor neurons; impairment of the function may help drive the amyotrophic lateral sclerosis disease process
Posted on Wednesday, March 12, 2014 - 14:28, By: Amy Madsen
TDP43 protein is involved in the transport of vital cargo within motor neurons, the muscle-controlling nerve cells that are lost in amyotrophic lateral sclerosis (ALS), a multinational research team reports. Further, disruption of the function results from ALS-causing mutations in the gene for the...
An MDA-supported study of 24 ALS patients showed those on high-calorie, high-carbohydrate tube feedings fared better than those on control or high-calorie, high-fat formulas
Posted on Wednesday, March 5, 2014 - 15:19, By: Margaret Wahl
A study supported in part by MDA has found that a high-calorie, high-carbohydrate diet is safe and well-tolerated in late-stage amyotrophic lateral sclerosis (ALS), that it leads to moderate weight gain, and that it may slow disease progression.
Researchers say the new model will increase understanding of the role FUS mutations play in ALS and help pinpoint therapeutic targets for FUS-associated ALS
Posted on Monday, February 10, 2014 - 11:45, By: Amy Madsen
A new research mouse model is the first to carry a mutation in the gene for the FUS protein that's known to cause human amyotrophic lateral sclerosis (ALS), an MDA-supported research team reports.
Animal models play a key role in disease research, and researchers say the new FUS model is an...